BACKGROUND AND PURPOSE: alpha(1)-Adrenoceptor agonists induce Ca(2+)-transients in endothelial cells (ECs) of arterioles. However, the presence of alpha(1)-adrenoceptors on arteriolar ECs has not been excluded, and the identity of alpha(1)-adrenoceptor subtypes in arterioles only has been inferred from pharmacology. Therefore, we determined which subtypes were expressed by vascular smooth muscle cells (VSMCs) and ECs, and which subtype mediated alpha(1)-adrenoceptor-induced constriction. EXPERIMENTAL APPROACH: EC Ca(2+)-transients in isolated, cannulated hamster cremasteric arterioles or freshly isolated ECs were studied using Fura 2. Arteriolar diameter was measured by video microscopy. alpha(1)-Adrenoceptor expression was assessed by western blot of whole-arteriolar homogenates and real-time RT-PCR on enzymatically isolated VSMCs and ECs. KEY RESULTS: Phenylephrine-induced constriction and EC Ca(2+)-transients were abolished by the alpha(1)-adrenoceptor antagonist prazosin (30 nM) in arterioles. Phenylephrine-induced constriction was inhibited by the alpha(1D)-adrenoceptor antagonist BMY 7378 (K(B)=2.96 nM) and the alpha(1A)-adrenoceptor antagonist 5-methylurapidil (K(B)=4.08 nM), suggesting a significant role for alpha(1D)-adrenoceptors. Western blots confirmed alpha(1D)-adrenoceptor expression, but did not detect alpha(1A)-adrenoceptors. VSMCs expressed alpha(1D)- and alpha(1A)-, but not alpha(1B)-, adrenoceptor transcripts. No alpha(1)-adrenoceptor transcripts were detected in ECs. Neither phenylephrine (10 microM) nor noradrenaline (0.1-1 microM) elicited Ca(2+)-transients in freshly isolated ECs, whereas the endothelium-dependent vasodilators methacholine (1 microM) and substance P (100 nM) consistently increased Ca(2+). CONCLUSIONS AND IMPLICATIONS: We reject the hypothesis that hamster cremasteric arteriolar ECs express alpha(1)-adrenoceptors and conclude that alpha(1)-adrenoceptor agonists predominantly act on VSMC alpha(1D)-adrenoceptors to cause vasoconstriction and a subsequent rise in EC Ca(2+).
BACKGROUND AND PURPOSE: alpha(1)-Adrenoceptor agonists induce Ca(2+)-transients in endothelial cells (ECs) of arterioles. However, the presence of alpha(1)-adrenoceptors on arteriolar ECs has not been excluded, and the identity of alpha(1)-adrenoceptor subtypes in arterioles only has been inferred from pharmacology. Therefore, we determined which subtypes were expressed by vascular smooth muscle cells (VSMCs) and ECs, and which subtype mediated alpha(1)-adrenoceptor-induced constriction. EXPERIMENTAL APPROACH: EC Ca(2+)-transients in isolated, cannulated hamster cremasteric arterioles or freshly isolated ECs were studied using Fura 2. Arteriolar diameter was measured by video microscopy. alpha(1)-Adrenoceptor expression was assessed by western blot of whole-arteriolar homogenates and real-time RT-PCR on enzymatically isolated VSMCs and ECs. KEY RESULTS:Phenylephrine-induced constriction and EC Ca(2+)-transients were abolished by the alpha(1)-adrenoceptor antagonist prazosin (30 nM) in arterioles. Phenylephrine-induced constriction was inhibited by the alpha(1D)-adrenoceptor antagonist BMY 7378 (K(B)=2.96 nM) and the alpha(1A)-adrenoceptor antagonist 5-methylurapidil (K(B)=4.08 nM), suggesting a significant role for alpha(1D)-adrenoceptors. Western blots confirmed alpha(1D)-adrenoceptor expression, but did not detect alpha(1A)-adrenoceptors. VSMCs expressed alpha(1D)- and alpha(1A)-, but not alpha(1B)-, adrenoceptor transcripts. No alpha(1)-adrenoceptor transcripts were detected in ECs. Neither phenylephrine (10 microM) nor noradrenaline (0.1-1 microM) elicited Ca(2+)-transients in freshly isolated ECs, whereas the endothelium-dependent vasodilators methacholine (1 microM) and substance P (100 nM) consistently increased Ca(2+). CONCLUSIONS AND IMPLICATIONS: We reject the hypothesis that hamster cremasteric arteriolar ECs express alpha(1)-adrenoceptors and conclude that alpha(1)-adrenoceptor agonists predominantly act on VSMC alpha(1D)-adrenoceptors to cause vasoconstriction and a subsequent rise in EC Ca(2+).
Authors: S Cotecchia; D A Schwinn; R R Randall; R J Lefkowitz; M G Caron; B K Kobilka Journal: Proc Natl Acad Sci U S A Date: 1988-10 Impact factor: 11.205
Authors: D A Schwinn; G I Johnston; S O Page; M J Mosley; K H Wilson; N P Worman; S Campbell; M D Fidock; L M Furness; D J Parry-Smith Journal: J Pharmacol Exp Ther Date: 1995-01 Impact factor: 4.030
Authors: Lydia W M Nausch; Adrian D Bonev; Thomas J Heppner; Yvonne Tallini; Michael I Kotlikoff; Mark T Nelson Journal: Am J Physiol Heart Circ Physiol Date: 2011-12-02 Impact factor: 4.733
Authors: Cam Ha T Tran; Mark S Taylor; Frances Plane; Sridevi Nagaraja; Nikolaos M Tsoukias; Viktoryiya Solodushko; Edward J Vigmond; Tobias Furstenhaupt; Mathew Brigdan; Donald G Welsh Journal: Am J Physiol Cell Physiol Date: 2012-01-25 Impact factor: 4.249
Authors: Miranda E Good; Daniela Begandt; Leon J DeLalio; Alexander S Keller; Marie Billaud; Brant E Isakson Journal: Biochem Soc Trans Date: 2015-06 Impact factor: 5.407
Authors: Sebastien Hayoz; Jessica Pettis; Vanessa Bradley; Steven S Segal; William F Jackson Journal: Am J Physiol Heart Circ Physiol Date: 2017-04-21 Impact factor: 4.733